Suven Life Sciences Ltd Revenue Down By 4.96%; PAT Down By 28.34% For The Third Quarter Ended December, 2015

HYDERABAD, INDIA (12 Feb’ 2016) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th Feb’ 2016 at Hyderabad. Financial Highlights for the 3rd Quarter ended December’ 2015 (QoQ):
Growth in revenue INR 1165 Mn vs Rs 1226 Mn - down by 4.96%
Growth in PAT INR 177 Mn vs. Rs 247 Mn - down by 28.34%
Growth in EBIDTA INR 286 Mn vs. Rs 365 Mn - down by 21.67%

Financial Highlights for the 9 months’ period ended December’ 2015:

Growth in revenue INR 3451 Mn vs Rs 4150 Mn - down by 16.84%
Growth in PAT INR 627 Mn vs. Rs 918 Mn - down by 31.72%
Growth in EBIDTA INR 952 Mn vs. Rs 1415 Mn - down by 32.70%

Suven’s thrust on innovative R&D in Drug Discovery continues with a spending of INR 462 Mn (13.38% on revenue) for the 9 months’ period ended Dec’ 2015.

For more information on Suven please visit our Web site at http://www.suven.com

Back to news